Merck Current Ratio 2010-2023 | MRK

Current and historical current ratio for Merck (MRK) from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Merck current ratio for the three months ending December 31, 2023 was .
Merck Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-12-31 $0.00B 0.00
2023-09-30 $31.95B $23.09B 1.38
2023-06-30 $29.98B $23.39B 1.28
2023-03-31 $33.40B $23.13B 1.44
2022-12-31 $35.72B $24.24B 1.47
2022-09-30 $33.56B $23.00B 1.46
2022-06-30 $32.12B $23.17B 1.39
2022-03-31 $31.18B $22.32B 1.40
2021-12-31 $30.27B $23.87B 1.27
2021-09-30 $31.06B $23.73B 1.31
2021-06-30 $28.67B $21.91B 1.31
2021-03-31 $26.91B $26.36B 1.02
2020-12-31 $27.76B $27.33B 1.02
2020-09-30 $26.58B $20.41B 1.30
2020-06-30 $29.34B $22.18B 1.32
2020-03-31 $26.17B $23.48B 1.12
2019-12-31 $27.48B $22.22B 1.24
2019-09-30 $26.14B $20.68B 1.26
2019-06-30 $24.30B $20.09B 1.21
2019-03-31 $25.35B $18.54B 1.37
2018-12-31 $25.88B $22.21B 1.17
2018-09-30 $26.84B $18.59B 1.44
2018-06-30 $24.06B $18.13B 1.33
2018-03-31 $24.09B $16.96B 1.42
2017-12-31 $24.77B $18.61B 1.33
2017-09-30 $27.92B $19.47B 1.43
2017-06-30 $28.17B $18.76B 1.50
2017-03-31 $31.53B $19.82B 1.59
2016-12-31 $30.61B $17.20B 1.78
2016-09-30 $29.44B $15.56B 1.89
2016-06-30 $27.93B $14.92B 1.87
2016-03-31 $28.77B $17.57B 1.64
2015-12-31 $29.75B $19.20B 1.55
2015-09-30 $28.57B $17.58B 1.63
2015-06-30 $28.32B $17.51B 1.62
2015-03-31 $32.93B $20.44B 1.61
2014-12-31 $32.61B $18.40B 1.77
2014-09-30 $34.72B $25.93B 1.34
2014-06-30 $33.59B $17.93B 1.87
2014-03-31 $41.24B $22.47B 1.84
2013-12-31 $35.69B $17.87B 2.00
2013-09-30 $37.77B $18.22B 2.07
2013-06-30 $37.00B $18.40B 2.01
2013-03-31 $35.24B $18.80B 1.87
2012-12-31 $34.86B $18.35B 1.90
2012-09-30 $36.23B $15.58B 2.33
2012-06-30 $35.64B $16.91B 2.11
2012-03-31 $34.34B $16.58B 2.07
2011-12-31 $33.18B $16.25B 2.04
2011-09-30 $34.11B $16.59B 2.06
2011-06-30 $32.37B $15.76B 2.05
2011-03-31 $31.02B $15.66B 1.98
2010-12-31 $29.06B $15.64B 1.86
2010-09-30 $27.76B $17.32B 1.60
2010-06-30 $26.25B $15.42B 1.70
2010-03-31 $28.25B $16.46B 1.72
2009-12-31 $28.43B $15.64B 1.82
2009-09-30 $29.67B $8.03B 3.70
2009-06-30 $29.23B $11.51B 2.54
2009-03-31 $26.19B $13.42B 1.95
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $328.029B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.190B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $389.835B 15.52
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
AstraZeneca (AZN) United Kingdom $204.098B 18.08
Pfizer (PFE) United States $156.755B 15.17
Sanofi (SNY) $123.368B 11.11
Innoviva (INVA) United States $0.992B 8.95